

## HR 7047

### Lowering Costs by Improving Biosimilar Uptake Act

**Congress:** 117 (2021–2023, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** Mar 9, 2022

**Current Status:** Referred to the Subcommittee on Health.

**Latest Action:** Referred to the Subcommittee on Health. (Mar 10, 2022)

**Official Text:** <https://www.congress.gov/bill/117th-congress/house-bill/7047>

### Sponsor

**Name:** Rep. Schrader, Kurt [D-OR-5]

**Party:** Democratic • **State:** OR • **Chamber:** House

### Cosponsors

*No cosponsors are listed for this bill.*

### Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Mar 10, 2022

### Subjects & Policy Tags

#### Policy Area:

Health

### Related Bills

*No related bills are listed.*

### Summary (as of Mar 9, 2022)

#### Lowering Costs by Improving Biosimilar Uptake Act

This bill allows for the omission of certain information relating to the strength of a product in a biosimilar application, as determined by the Food and Drug Administration.

### Actions Timeline

- **Mar 10, 2022:** Referred to the Subcommittee on Health.
- **Mar 9, 2022:** Introduced in House
- **Mar 9, 2022:** Referred to the House Committee on Energy and Commerce.